To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Centocor Ortho Biotech Inc. Acquires RespiVert Ltd., Strengthens Pulmonary Focus
02-06-2010: Centocor Ortho Biotech Inc. announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases. The company's lead compounds, RV-568 and RV-1088, narrow spectrum kinase inhibitors with a unique profile of anti-inflammatory activities, are progressing into clinical development as potential first-in-class treatments for moderate to severe asthma, Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF). The clinical development of RV-568 and RV-1088 will be led by RespiVert in collaboration with scientists at Centocor Research and Development, Inc. The company is not disclosing financial terms.
"The RespiVert compounds offer the potential for a new class of medicines for patients with severe lung disease who are insensitive to inhaled corticosteroids," said Susan Dillon, Ph.D., Global Therapeutic Area Head, Immunology, Centocor Research and Development, Inc. "The addition of RespiVert's expert scientific team and discovery platforms for inhaled medicines strengthens our capabilities and further builds our pipeline of novel oral and biologic therapies for serious pulmonary diseases."
With the acquisition of RespiVert, Centocor Ortho Biotech gains a portfolio of first-in-class, early-stage inhaled treatments for serious lung diseases. RespiVert will continue to maintain its research and discovery presence in London from the Imperial BioIncubator, which is based at the campus of Imperial College London. RespiVert employees will continue to lead ongoing research and drug discovery efforts.
Dr. Garth Rapeport, Chief Executive Officer of RespiVert, who is remaining with RespiVert following the acquisition, said, "We believe that our focused discovery efforts in pulmonary disease offer a unique opportunity to bring completely new treatment options to patients who suffer from severe, chronic respiratory diseases including Chronic Obstructive Pulmonary Disease, severe asthma and Cystic Fibrosis."
This is where you can add this news to your personal favourites
- 1Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 2Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 3Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
- 4Researchers divide enzyme to conquer genetic puzzle
- 5Merck & Co., Inc. Opens Asia Pacific Regional Headquarters in Singapore
- 6Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.
- 7Sanofi-aventis to acquire Oenobiol
- 8Pharmexa enters into an agreement regarding GV1001 with the Korean company KAEL Co. Ltd
- 9DSM Sinochem Pharmaceuticals opens new 6-APA intermediate plant in China
- 10Pharmsynthez granted Orphan Drug Designation for Virexxa in the US
- History of analytical measuring technology in Jena
- Resolutions of the Annual General Meeting of Evotec
- ZEISS to acquire Xradia to complement its microscopy business
- DHL launches industry-changing temperature controlled Life Sciences air frei ...
- Novasep appoints Udo Steinhauer as fine chemicals market director
- The Facebook effect: Social media dramatically boosts organ donor registration
- Psychiatric disorders linked to a protein involved in the formation of long-term memories
- Study finds racial and ethnic disparities in usage of specialty services for children with autism
- Bacterium breaks down grass into biofuel
- Be gone, bacteria